

## Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Yin Z, Yu M, Ma T, *et al.* Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. *J Immunother Cancer* 2021;9:e001698. doi: 10.1136/jitc-2020-001698

This article has been corrected since it was first published. Amir Abaas Momtazi-Borojeni's affiliation has been updated to 'Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran'.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2022;10:e001698corr2. doi:10.1136/jitc-2020-001698corr2

